|
|
|
Insider
Information: |
Bradbury Daniel |
Relationship: |
Director |
City: |
San Diego |
State: |
CA |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
8 |
|
Direct
Shares |
232,105 |
|
Indirect Shares
|
3,170,485 |
|
|
Direct
Value |
$3,195,404 |
|
|
Indirect Value
|
$6,335,652 |
|
|
Total
Shares |
3,402,590 |
|
|
Total
Value |
$9,531,057 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
0
|
0
|
Stock
price went up :
|
0
|
0
|
Stock
price went down : |
0
|
0
|
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
Percentage
Gain/Loss : |
0.0%
|
0.0%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Amylin Pharmaceuticals Inc |
AMLN |
President & Chief Exec... |
2012-08-08 |
0 |
2012-08-08 |
0 |
Premium* |
|
Paratek Pharmaceuticals Inc |
PRTK |
Director |
2006-05-09 |
35,714 |
|
0 |
Premium* |
|
Illumina Inc |
ILMN |
Director |
2017-05-25 |
15,324 |
2008-05-16 |
0 |
Premium* |
|
Corcept Therapeutics Inc |
CORT |
Director |
2012-11-21 |
0 |
2019-02-07 |
130,575 |
Premium* |
|
Geron Corporation |
GERN |
Director |
2014-05-09 |
142,776 |
2019-03-29 |
51,323 |
Premium* |
|
Equillium Inc |
EQ |
Chief Executive Office... |
2018-10-16 |
0 |
2018-10-16 |
2,969,596 |
Premium* |
|
Castle Biosciences Inc |
CSTL |
Director |
2024-05-25 |
13,291 |
2024-10-07 |
18,991 |
Premium* |
|
Nuvation Bio Ord Shs Class A |
NUVB |
Director |
2021-02-10 |
25,000 |
2021-02-10 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 1 of 1
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
CSTL |
Castle Biosciences Inc |
Director |
|
2019-07-29 |
4 |
A |
$0.00 |
$908,838 |
I/I |
908,578 |
908,578 |
0 |
- |
|
AMLN |
Amylin Pharmaceuticals In... |
President & Chief Executive Of |
|
2012-08-08 |
4 |
A |
$31.00 |
$6,681,306 |
D/D |
215,526 |
313,471 |
0 |
- |
|
AMLN |
Amylin Pharmaceuticals In... |
President & Chief Executive Of |
|
2012-08-08 |
4 |
D |
$31.00 |
$6,681,306 |
D/D |
(215,526) |
97,945 |
0 |
- |
|
GERN |
Geron Corporation |
Director |
|
2014-05-09 |
4 |
B |
$1.75 |
$249,858 |
D/D |
142,776 |
142,776 |
2.39 |
- |
|
AMLN |
Amylin Pharmaceuticals In... |
President & Chief Executive Of |
|
2012-08-08 |
4 |
D |
$31.00 |
$3,880,623 |
I/I |
(125,181) |
0 |
0 |
- |
|
CORT |
Corcept Therapeutics Inc |
Director |
|
2014-05-09 |
4 |
B |
$1.79 |
$224,213 |
I/I |
125,000 |
304,000 |
2.1 |
- |
|
CORT |
Corcept Therapeutics Inc |
Director |
|
2012-11-23 |
4 |
B |
$1.40 |
$138,481 |
I/I |
99,000 |
179,000 |
2.1 |
- |
|
AMLN |
Amylin Pharmaceuticals In... |
President & Chief Executive Of |
|
2012-08-08 |
4 |
D |
$31.00 |
$3,036,301 |
D/D |
(97,945) |
0 |
0 |
- |
|
CORT |
Corcept Therapeutics Inc |
Director |
|
2012-11-21 |
4 |
B |
$1.38 |
$110,504 |
I/I |
80,000 |
80,000 |
2.1 |
- |
|
CSTL |
Castle Biosciences Inc |
Director |
|
2022-04-26 |
4 |
A |
$0.00 |
$0 |
I/I |
60,997 |
246,249 |
0 |
- |
|
CSTL |
Castle Biosciences Inc |
Director |
|
2023-07-07 |
4 |
AS |
$20.39 |
$1,019,500 |
I/I |
(50,000) |
67,805 |
0 |
- |
|
EQ |
Equillium Inc |
Chief Executive Officer |
|
2018-10-16 |
4 |
A |
$11.20 |
$543,144 |
I/I |
48,495 |
2,969,596 |
0 |
- |
|
AMLN |
Amylin Pharmaceuticals In... |
President & Chief Executive Of |
|
2011-10-04 |
4 |
OE |
$5.73 |
$257,850 |
I/I |
45,000 |
41,021 |
0 |
- |
|
AMLN |
Amylin Pharmaceuticals In... |
President & Chief Executive Of |
|
2010-02-18 |
4 |
OE |
$14.28 |
$636,547 |
I/I |
44,573 |
79,691 |
0 |
- |
|
AMLN |
Amylin Pharmaceuticals In... |
President & Chief Operating |
|
2007-03-22 |
4 |
OE |
$2.91 |
$488,911 |
D/D |
39,269 |
52,240 |
0 |
- |
|
AMLN |
Amylin Pharmaceuticals In... |
President & Chief Executive Of |
|
2012-07-26 |
4 |
OE |
$11.95 |
$430,200 |
D/D |
36,000 |
103,615 |
0 |
- |
|
AMLN |
Amylin Pharmaceuticals In... |
President & Chief Executive Of |
|
2010-02-18 |
4 |
D |
$17.82 |
$625,803 |
I/I |
(35,118) |
44,573 |
0 |
- |
|
AMLN |
Amylin Pharmaceuticals In... |
President & Chief Executive Of |
|
2012-01-10 |
4 |
A |
$0.00 |
$0 |
D/D |
30,000 |
62,178 |
0 |
- |
|
AMLN |
Amylin Pharmaceuticals In... |
President & Chief Executive Of |
|
2012-03-06 |
4 |
A |
$0.00 |
$0 |
D/D |
30,000 |
88,745 |
0 |
- |
|
CORT |
Corcept Therapeutics Inc |
Director |
|
2015-11-23 |
4 |
S |
$4.96 |
$148,923 |
I/I |
(30,000) |
207,925 |
0 |
- |
|
AMLN |
Amylin Pharmaceuticals In... |
President & Chief Executive Of |
|
2011-10-04 |
4 |
D |
$8.75 |
$253,566 |
I/I |
(28,979) |
40,275 |
0 |
- |
|
AMLN |
Amylin Pharmaceuticals In... |
President & Chief Executive Of |
|
2010-11-22 |
4 |
OE |
$11.13 |
$278,125 |
I/I |
25,000 |
74,573 |
0 |
- |
|
AMLN |
Amylin Pharmaceuticals In... |
President & Chief Executive Of |
|
2011-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
25,000 |
32,178 |
0 |
- |
|
CORT |
Corcept Therapeutics Inc |
Director |
|
2019-02-07 |
4 |
GD |
$0.00 |
$0 |
I/I |
25,000 |
130,575 |
0 |
- |
|
NUVB |
Nuvation Bio Ord Shs Clas... |
Director |
|
2021-02-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
25,000 |
25,000 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|